Overview

Empagliflozin Versus Sitagliptin Therapy for Improvement of Myocardial Perfusion Reserve in Diabetic Patients With Coronary Artery Disease

Status:
Completed

Trial end date:
2019-08-01

Target enrollment:

Participant gender:

Summary

This trial evaluates the effects of Empagliflozin versus Sitagliptin, in addition to standard of care, on global myocardial perfusion reserve using dynamic single-photon emission computed tomography (SPECT) images.

Phase:

Phase 4

Details

Lead Sponsor:

CHEOL WHAN LEE, M.D., Ph.D

Treatments:

Empagliflozin
Sitagliptin Phosphate